| http://dbpedia.org/ontology/abstract
|
Anti-interleukin-6 agents are a class of t … Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6 agents have been sought. In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors. The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. The second, siltuximab (Sylvant), is directed against IL-6 itself. Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8-negative patients with multicentric Castleman's disease. Siltuximab was also tested in the phase I/II study for therapy of patients with metastatic castration-associated prostate cancer in combination with docetaxel and in renal cell carcinoma; phase II trials in ovarian cancer resulted in 39% of patients showed disease stabilization via IL-6-regulated downregulation of CCL2, CXCL12 and VEGF. Tocilizumab was first used in large-cell lung carcinoma. In phase I/II trial of tocilizumab in ovarian cancer EGFR pathway upregulation was observed and after inhibition of this pathway by gefitinib tumor growth was decreased both in vitro and in vivo. Sarilumab was approved by US FDA in 2017 for rheumatoid arthritis. Several agents are in clinical trials: olokizumab (CDP6038) elsilimomab, clazakizumab (BMS-945429, ALD518), sirukumab (CNTO 136), (BCD-089), and an apparent macrophage-specific inhibitor of the p38 mitogen-activated protein kinase pathway. ALX-0061. e.g. for rheumatoid arthritis : clazakizumab, olokizumab, sarilumab and sirukumab have all reported encouraging phase 2 results. Sirukumab is in multiple phase 3 trials. Agents in pre-clinical development include , FE301,and FM101.cal development include , FE301,and FM101.
|
| http://dbpedia.org/ontology/wikiPageID
|
25155071
|
| http://dbpedia.org/ontology/wikiPageLength
|
12085
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1106268034
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Luteolin +
, http://dbpedia.org/resource/COVID-19 +
, http://dbpedia.org/resource/Category:Immunosuppressants +
, http://dbpedia.org/resource/Cytokine +
, http://dbpedia.org/resource/US_FDA +
, http://dbpedia.org/resource/TNF_inhibitor +
, http://dbpedia.org/resource/P38_mitogen-activated_protein_kinase +
, http://dbpedia.org/resource/CXCL12 +
, http://dbpedia.org/resource/Sarilumab +
, http://dbpedia.org/resource/Levilimab +
, http://dbpedia.org/resource/ARGX-109 +
, http://dbpedia.org/resource/CPSI-2364 +
, http://dbpedia.org/resource/Eccentric_exercises +
, http://dbpedia.org/resource/Tocilizumab +
, http://dbpedia.org/resource/Docetaxel +
, http://dbpedia.org/resource/Ovarian_cancer +
, http://dbpedia.org/resource/Interleukin-6_receptor +
, http://dbpedia.org/resource/HHV-8 +
, http://dbpedia.org/resource/Rheumatoid_arthritis +
, http://dbpedia.org/resource/Myokine +
, http://dbpedia.org/resource/Renal_cell_carcinoma +
, http://dbpedia.org/resource/Castleman%27s_disease +
, http://dbpedia.org/resource/Interleukin_6 +
, http://dbpedia.org/resource/Asthma +
, http://dbpedia.org/resource/Epidermal_growth_factor_receptor +
, http://dbpedia.org/resource/Gefitinib +
, http://dbpedia.org/resource/COVID-19_pandemic +
, http://dbpedia.org/resource/Obesity +
, http://dbpedia.org/resource/Sirukumab +
, http://dbpedia.org/resource/Siltuximab +
, http://dbpedia.org/resource/Large-cell_lung_carcinoma +
, http://dbpedia.org/resource/Acute_respiratory_distress_syndrome +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/VEGF +
, http://dbpedia.org/resource/CCL2 +
, http://dbpedia.org/resource/Prostate_cancer +
, http://dbpedia.org/resource/Elsilimomab +
, http://dbpedia.org/resource/Clazakizumab +
, http://dbpedia.org/resource/Olokizumab +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Interleukin_receptor_modulators +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Rp +
, http://dbpedia.org/resource/Template:Short_description +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Immunosuppressants +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Therapeutics +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Anti-IL-6?oldid=1106268034&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Anti-IL-6 +
|
| owl:sameAs |
https://global.dbpedia.org/id/4Rn7c +
, http://yago-knowledge.org/resource/Anti-IL-6 +
, http://dbpedia.org/resource/Anti-IL-6 +
, http://www.wikidata.org/entity/Q4774187 +
, http://rdf.freebase.com/ns/m.09gl2lq +
|
| rdf:type |
http://dbpedia.org/class/yago/WikicatImmunosuppressants +
, http://dbpedia.org/class/yago/Medicine103740161 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/class/yago/Immunosuppressant103562958 +
, http://dbpedia.org/class/yago/Drug103247620 +
, http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
|
| rdfs:comment |
Anti-interleukin-6 agents are a class of t … Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6 agents have been sought. In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors. Tocilizumab was first used in large-cell lung carcinoma. In phase I/II trial of tocilizumab in ovarian cancer EGFR pathway upregulation was observed and after inhibition of this pathway by gefitinib tumor growth was decreased both in vitro and in vivo. Sarilumab was approved by US FDA in 2017 for rheumatoid arthritis.y US FDA in 2017 for rheumatoid arthritis.
|
| rdfs:label |
Anti-IL-6
|
